

2
3 **Phytochemical and toxicological study of**
4 ***Neptunia oleracea* Lour. (Mimosaceae) extracts,**
5 **plant use in traditional medicine**
6
7

8
9
10
11 **ABSTRACT**
12

Neptunia oleracea (Lour.) *Mimosaceae* is a plant commonly used in traditional medicine. This plant was fluently used in traditional medicine for the treatment of several pathologies such as dysentery, jaundice, leucorrhoea, troubles of eareache, etc.

Aims: the purpose study was to carried out the phytochemical profile, to study the acute toxicity of extracts from this medicinal plant and evaluate the effect of these extracts on intestinal motility *in vivo*

Methodology: Phytochemical screening and acute toxicity test were performed using standards methods. The effects of *N. oleracea* extracts on intestinal motility consisted in evaluating the effect of these extracts on normal and acetylcholin-induced transit.

Results: Phytochemical screening revealed the presence of several chemical groups including steroids, triterpenes, flavonids, tannins, saponins, etc.

The toxicological study gave an estimated LD50 of 5000 mg/kg for all extracts. The investigation of effect of extracts on intestinal peristalsis in mice showed that the aqueous and hydro-ethanolic extracts of *Neptunia oleracea* stimulate normal intestinal transit by 1.29 and 8.54% respectively at the dose of 50 mg/kg b.w. but inhibit it at higher doses. These extracts potentiate acetylcholin-induced intestinal transit by 23.9% and 14.39% respectively at 500 mg/kg body weight.

Conclusion: this study showed that the extracts of *Neptunia oleracea* contain secondary metabolites and have practically no toxic effect. This could justify the many forms of use of this plant in traditional medicine.

13
14 *Keywords: Neptunia oleracea; acute toxicity, NMRI mice, Intestinal transit, Burkina Faso*
15
16
17
18
19

20 **1. INTRODUCTION**

21 The therapeutic use of medicinal plants is still very present in some countries of the world
22 and especially in developing countries despite the progress of pharmacology [1]. In Africa,
23 medicinal plants are valuable resources for the majority of rural populations, where more
24 than 80% uses theses plants for health care [2]. In Burkina Faso, traditional medicine and
25 pharmacopoeia are the main source of primary health care for 70% of the population [3].
26 *Neptunia oleracea* (*N. oleracea*) is one of the many plants used in traditional medicine in
27 Burkina Faso. This plant is used to treat many diseases including dysentery, skin diseases,
28 syphilis, earaches, and guinea worm infections [4].

29 Several authors have expressed interest in the pharmacological and chemical aspect of this
30 plant. Thus, phytochemical studies have revealed several chemical groups including
31 flavonoids, anthraquinones and tannins in the aqueous and hydro-ethanolic extracts from *N.*
32 *oleracea* leaves [5, 6]. Pharmacological studies have shown that *N. oleracea* has astringent,
33 antimicrobial and anti-tumor and hepatoprotective properties [5, 7, 8].

34 However, there are very few data on the toxicity of this plant. Several studies around the
35 world have however reported serious side effects related to the use of medicinal plants. It is
36 recognized that toxic drugs cause serious liver damage and are responsible for about 10%
37 of acute liver failure and 5% of itching [9, 10]. In Morocco, plant intoxications are responsible
38 for 14.2% of deaths [11]. According to the Pharmacotherapeutic Information Bulletin of
39 Burkina Faso (2015), more than 22% of renal failure is due to medicinal plants. However,
40 some traditional health practitioners and populations are not always aware of the toxicity of
41 medicinal plants. Safety and security are therefore important criteria to consider before
42 administering herbal products. That is why WHO recommends that medicinal plants should
43 be studied to better understand their therapeutic properties and to ensure their safe use [12].
44 The purpose of this work was therefore to evaluate the toxicity of *N. oleracea* extracts to
45 allow a better safety of its use in traditional medicine.

46 **2. MATERIAL AND METHODS**

47 **2.1. Plant Material**

48
49 The plant material consisted of *N. oleracea* leaves harvested in August 2014 in
50 Ouagadougou (Burkina Faso). The plant was identified and authenticated at the Burkina Faso
51 National Herbarium (HNBU) where a voucher specimen was deposited under N^o. 8729. The
52 leaves were dried in shade, away from dust and then crushed using a laboratory crusher
53 (Blade Crusher, Gladiator East. 1931 Type BN 1 Mach. 40461 1083). The vegetable powder
54 obtained was used to prepare aqueous and hydro-ethanolic extracts.

55 56 57 **2.2. Animal**

58 Toxicological studies were conducted on male and female NMRI mice weighing between 23
59 and 31 g. The animals were obtained from the "Institut de Recherche en sciences de la
60 Santé" (IRSS) pet shop and were reared in controlled room temperature (23-25°C) with 40-
61 65% of humidity. They were fed with protein enriched wheat cake (29%) and tap water.
62 These animals were subjected to 12 hours of illumination and 12 hours of darkness. The
63 mice were evenly distributed per sex in cages with three mice per cage.

64 65 66 67 **2.3. Aqueous decoction preparation**

68 A portion of 100 g of the vegetable powder was introduced into a flask containing 700 mL of
69 distilled water. The mixture was heated under reflux for 1 hour. At the end of this operation,
70 the decocted extract obtained was filtered using a nylon fabric and then centrifuged at 2000
71 rpm for 10 minutes. The filtrate obtained was dried in an oven at 45°C under ventilation. The
72 dry extract obtained was weighed to determine the extraction yield.

73

74 **2.4. Hydro-ethanolic decoction preparation**

75 A sample of 100 g of vegetable powder was placed in a flask containing 500 mL of 80%
76 hydro-ethanolic solution. The mixture was boiled under reflux for 1 hour. The decoction, after
77 cooling, was filtered on Wattman N°5 paper and concentrated with rotavapor at 60 to 70°C.
78 The concentrated extract was dried in an oven at 45°C under ventilation and weighed to
79 determine the extraction yield.

80

81 **2.5. Alkaloids-rich fraction preparation**

82 The alkaloids-rich fraction was prepared according to the protocol described by Mbodj
83 (2003) [13]. To 100 mL of the aqueous or hydro-ethanolic decoction was added a sodium
84 carbonate solution (Na₂CO₃) at 5% until pH8. The mixture was transferred into 250 mL
85 separating funnel and extracted by liquid/liquid sharing with 3x 25 mL of chloroform. After
86 settling, the organic phase was recovered and filtered on filter paper. The filtrate obtained
87 was concentrated under reduced pressure with rotavapor. The dry extract obtained
88 constitutes the alkaloidal fraction.

89

90 **2.6. Phytochemical screening**

91 The phytochemical screening was performed on the extracts in solution using the method
92 described by Ciulei (1982) [14] and adapted by the phytochemistry laboratory of the Institute
93 for Research in Health Sciences (IRSS).

94

95 **2.7. Acute toxicity study**

96 The acute toxicity study was conducted using the OECD N° 423 guideline [15].
97 The test was performed on two groups of three healthy female mice weighing between 23
98 and 31 g. The mice were fasted four hours before the test.
99 A single dose of 2000 mg/kg body weight (b.w.) of each extract was administered orally
100 using a gastric tube. After administration of the extracts, the animals were observed every 30
101 minutes for 2 hours. After the two hours observation, the animals were fed and then
102 observed daily for 14 days. Mortality and any behavioural change were recorded during the
103 observation period.

104

105

2.8. Effects of *N. oleracea* extracts on intestinal peristalsis *in vivo*

106 The study of the effects of *N. oleracea* aqueous and hydro-ethanolic extracts on intestinal
107 motility consisted in evaluating the effect of these extracts on normal and acetylcholin-
108 induced transit. This study was carried out according to an adaptation of the protocol
109 described by Tagne *et al.* (2015) [16].

110 The normal transit study was performed using four groups of mice. The animals were fasted
111 for 18 hours after which we administered the extracts. The first group (negative control)
112 received orally 0.5 mL of 40% activated charcoal in distilled water. The three other groups
113 were administered respectively loperamide at 5 mg/kg, extract at dose of 50 mg/kg and 500
114 mg/kg b.w., orally. The mice from these three groups received 0.5 mL of 40% activated
115 charcoal 30 minutes after extracts administration. All the mice were sacrificed 30 minutes
116 after the charcoal administration. The distance travelled by the charcoal in the small intestine
117 and the whole length of the intestine were measured.

118 Intestinal transit was calculated according to the following formula:

119

120 % Intestinal transit = $\frac{\text{distance travelled by activated charcoal}}{\text{total length of the small intestine}} * 100$

121

122 For acetylcholin-induced intestinal transit study, three (3) groups of four mice each per
 123 extract were used. After 18 hours fasting, 0.1 mg/kg of acetylcholine were administered
 124 intraperitoneally (i.p.) to the first group (positive control). The two other groups received
 125 acetylcholine at 0.1 mg/kg *i.p.* and the extract respectively at 50 and 500 mg/kg b.w.

126 Thirty (30) minutes later, all the mice received 0.5 mL of activated charcoal at 40% in
 127 distilled water.

128 The mice were sacrificed 30 minutes after the activated charcoal administration. The
 129 distance travelled by the activated charcoal in the small intestine and the total length of the
 130 small intestine were measured.

131 Intestinal transit was calculated according to the following formula:

132

133 % Intestinal transit = $\frac{\text{distance travelled by activated charcoal}}{\text{total length of the small intestine}} * 100$

134

135 2.9. Statistical analysis

136 Both qualitative and quantitative data were presented in tables. The results of *in vivo* test
 137 were expressed as mean ± SD (Standard deviation). The statistical analyses of variance
 138 were done by ONE WAY ANOVA followed by the Dunnett's multiple comparison tests
 139 through the Graph Pad Prism 5.0 program. Differences were considered significant if p <
 140 0.05.

141

142 3. RESULTS

143 3.1. Extraction yields

144 After the aqueous and hydro-ethanolic decoctions preparation the extraction yields were
 145 determined. The extraction yields in terms of dry extract ranged from 16.06% to 0.54%
 146 (Table 1).

147

148 **Table 1:** Extraction yields from *N. oleracea* aqueous and hydro-ethanolic decoction yields
 149 (n=3)

Extracts	Hydro-alcoholic decoction (%)	Aqueous decoction (%)
Crude extraction	15.93 ± 0.35	16.06 ± 1.59
Alkaloids fraction	0.54	0.56

150

151

152

153 3.2. Phytochemical screening

154 The results of phytochemical screening of *N. oleracea* aqueous and hydro-ethanolic extracts
 155 showed the presence of several chemical groups such as flavonoids, saponins tannins,
 156 coumarins, and carbohydrates (Table 2).

157

158 **Tableau 2:** phytochemical profil of *N. oleracea* aqueous and hydro-ethanolic decoction

Chemical compounds	Aqueous decoction	Hydro-ethanolic decoction
Steroids and triterpenoids	+	+
Saponins	+	+
Polyphenolic compounds (tannins)	++	++
Flavonids	±	+
Anthocyanosides	+	+
Coumarins	+	+
Alcaloids	-	-
Carbohydrates (oses)	+	+

159 ++ = abundant; + = scarce; ± = trace; - = absent

160

161 **3.3. Oral acute toxicity study of *N. oleracea* aqueous and hydro-ethanolic**
 162 **extracts**

163 The acute toxicity study showed that *N. oleracea* extracts did not caused mortality in NMRI
 164 mice when administered orally at 2000 mg/kg b.w. Any symptoms of intoxication related to
 165 the extract were not observed during the 72 hours of observation following the administration
 166 of the extracts and after two weeks of observation. The results of the oral acute toxicity of *N.*
 167 *oleracea* extracts are presented in table 3.

168

169 **Table 3:** Results of oral acute toxicity study of *N. oleracea* aqueous and hydro-éthanolic
 170 extracts in mice at 2000 mg/kg b.w. (n=3)

171

Type of extracts	First test		Second test	
	Mortality	Mortality rate (%)	Mortality	Mortality rate (%)
Aqueous decoction	0/3	0	0/3	0
Hydro-ethanolic decoction	0/3	0	0/3	0

172

173 In view of the results of this table, the LD₅₀ of *N. oleracea* extracts is estimated to be 5000
 174 mg/kg b.w. when administered orally, according to the OECD test guidelines.

175

176

177

178 **3.4. Oral acute toxicity of the alkaloids fraction of *N. oleracea* aqueous and**
 179 **hydro-ethanolic extracts**

180 The oral administration of the alkaloids fraction of *N. oleracea* at 2000 mg/kg b.w. did not
 181 caused mortality or symptoms of intoxication (Table 4).

182 **Table 4:** oral acute toxicity of the alkaloids fractions from *N. oleracea* aqueous and hydro-
 183 ethanolic extracts in mice at 2000 mg/kg b.w. (n=3).

First test		Second test	
Mortality	Mortality rate (%)	Mortality	Mortality rate (%)
0/3	0	0/3	0

184 The oral LD₅₀ of the alkaloids fraction of aqueous and hydro-ethanolic extracts of *N.*
 185 *oleracea* is estimated to be 5000 mg/kg b.w. according to the OECD (2001) test
 186 scheme.

187

188 3.5. Effects of aqueous and hydro-ethanolic extracts from *N. oleracea* on 189 intestinal transit *in vivo*

190 The results of the effects of aqueous and hydro-ethanolic extracts from *N. oleracea*, on
 191 normal intestinal transit, were presented in table 5. These results show that at 50 mg/kg b.w.,
 192 aqueous and hydro-ethanolic extracts from *N. oleracea* stimulated the normal transit of 1.29
 193 and 8.54% respectively while acetylcholine stimulated this transit of 9.68% for at dose of
 194 0.1mg/kg b.w. However, at 500 mg/kg b.w., these extracts inhibited normal transit of 2.58
 195 and 2.07% respectively for aqueous and hydro-ethanolic extracts. Loperamide inhibited this
 196 transit of 20.18% at 5 mg/kg b.w.; the normal intestinal transit was 64.17 ± 8.05.

197

198 **Table 5:** Effect of *N. oleracea* extracts on normal intestinal transit

199

Treatment	Dose (mg/kg)	Intestinal transit	Inhibition rate (%)	Stimulation rate (%)
Normal control		64.17 ± 8.05		
Acetylcholine	0.1	73.84 ± 4.63		9.68
Loperamide	5	43.98 ± 4.81	20.18	
Aqueous extract	50	65.45 ± 12.98		1.29
	500	61.57 ± 8.79	2.59	
Hydro-ethanolic extract	50	72.71 ± 3.10		8.54
	500	62.09 ± 1.77	2.07	

200

201 Table 6 presents the results of acetylcholin-induced intestinal transit test. These results
 202 show that the aqueous and hydro-ethanolic extracts from *N. oleracea* potentiated the
 203 intestinal transit induced by acetylcholine. At a dose of 50 mg/kg, aqueous and hydro-
 204 ethanolic extracts from *N. oleracea* increased acetylcholin-induced intestinal transit of 10.85
 205 and 7.04% respectively. At 500 mg/kg body weight, the aqueous extract increased
 206 acetylcholin-induced intestinal transit of 23.90%. At the same dose, hydro-ethanolic extract
 207 stimulated acetylcholin-induced intestinal transit of 14.39%.

208

209

210

211

212 **Table 6:** Effect of aqueous and hydro-ethanolic extracts from *N. oleracea* on acetylcholin-
 213 induced intestinal transit

Treatment	Dose (mg/kg)	Intestinal transit	Stimulation rate (%)
Normal control		64.17 ± 8.05	
Acetylcholine	0.1	73.84 ± 4.63	9.68

Aqueous extract	50	75.02 ± 4.09	10.85
	500	88.07 ± 7.65	23.90
Hydro-ethanolic extract	50	71.21 ± 3.48	7.034
	500	78.56 ± 3.45	14.39

214

215 4. DISCUSSION

216 Plants produce a variety of natural substances including secondary metabolites to protect
 217 against predators and pathogens. These secondary metabolites are most often responsible
 218 of the toxicity of certain plants [17]. According to some authors, 20% of plants were once
 219 used as abortive, 20% for criminal purposes, 15% for witchcraft and 10% for psychoactive
 220 plants [18]. Among the toxic secondary metabolites of plants are coumarins, which have
 221 spasmolytic properties. Some of them (hydroxicoumarins) cause haemorrhagic diarrhea,
 222 haematuria and dyspnea, which can lead to death. Toxic diterpenoids induce violent
 223 digestive disorders or severe skin or eye irritations. Tannins cause reduced growth in
 224 animals by inhibiting the metabolic use of amino acids after absorption [19].

225 Phytochemical screening of aqueous and hydro-ethanolic extracts of *N. oleracea* leaves
 226 revealed the presence of several chemical groups including steroids, flavonoids, tannins,
 227 saponins, etc. These results support those of other authors who have found the same
 228 chemical groups in different extracts from different parts of this plant [5, 20, 21].

229 The results of the oral acute toxicity of aqueous and hydro-ethanolic extracts from *N.*
 230 *oleracea* and the alkaloids fractions showed that at 2000 mg/kg b.w., these extracts did not
 231 cause mortality in mice. During the observation period, no signs of intoxication were
 232 observed. The oral LD₅₀ of these extracts is estimated to be 5000 mg/kg. These extracts can
 233 be classified in category 5 of substances not known to present an acute hazard according to
 234 the WHO classification [22]; the globally harmonized OECD and United Nation classification
 235 system [15, 23].

236 These results support those of other authors who have shown that aqueous and hydro-
 237 ethanolic extracts of *N. oleracea* do not cause mortality in rats at 2000 mg/kg b.w. when
 238 administrate orally [5, 7]. The results of our work confirm that the aqueous and hydro-
 239 ethanolic extracts of *N. oleracea* and their alkaloids fractions are weakly toxic as found in
 240 previous works. This low toxicity could support the multiple uses of this plant in traditional
 241 medicine.

242 However, since this study focused on acute toxicity, repeated-dose toxicity studies will
 243 provide a better understanding of the toxic potential of these extracts.

244 The results of the intestinal transit study showed that acetylcholine stimulated intestinal
 245 transit of 9.68% at 0.1 mg/kg. The aqueous and hydro-ethanolic extracts of *N. oleracea*
 246 stimulated normal intestinal transit at low dose while at high doses both extracts inhibited
 247 normal transit. At 50 and 500 mg/kg, these extracts stimulated acetylcholin-induced intestinal
 248 transit.

249 The motricity of the gastrointestinal tract is controlled by the cholinergic system, of which
 250 acetylcholine is one of the neurotransmitters [24]. It is synthesized by enteric excitatory motor
 251 neurons and its binding to the M3 receptor of the gastrointestinal tract leads to an increase
 252 of motility, tone and intestinal peristalsis [25]. Acetylcholine has ability to activate parietal
 253 cells and G cells as well as enterochromaffin cells (ECL). G cells and ECL cells produce
 254 gastrin and histamine respectively. Gastrin, histamine and acetylcholine are hormones that
 255 promote digestion by stimulating the secretion of protons. In addition, acetylcholine and
 256 cholinergic agonists by activating muscarinic M3 and M1 receptors inhibit the absorption of
 257 sodium and chloride ions and stimulate the secretion of these ions and water into the colon
 258 [26].

259 Apart from acetylcholine, vasoactive intestinal peptide (VIP), nitric oxide (NO) and ATP are
 260 neurotransmitters synthesized by inhibitory neurons whose release induces muscle

261 relaxation of the gastrointestinal tract [27]. The aqueous and hydroethanolic extracts of *N.*
262 *oleracea* is believed to act as an acetylcholine agonist on M3 muscarinic receptors, G cells
263 or ECL cells in the gastrointestinal tract, increasing the tone and contractions of the intestine,
264 resulting in increased intestinal transit. This mechanism may also explain the exacerbation of
265 the effect of acetylcholine on intestinal transit. The inhibition of normal intestinal transit by
266 aqueous and hydro-ethanolic extracts from *N. oleracea* at high-dose would be related to the
267 capacity of metabolites present in these extracts to occupy other receptors whose activation
268 would cause adverse effects of acetylcholine such as opioid receptors (μ). Indeed, the
269 activation of muscular opioid receptors (μ) in the gastrointestinal tract reduces motility and
270 propulsive contractions and gastric emptying, but leads to an increase in muscle tone and
271 non-propulsive (segmental) contractions [28]. It is also possible that these extracts, in high
272 doses, inhibit intestinal motility by acting directly on circular muscles and long intestinal
273 muscles such as loperamide [29]. The traditional use of *N. oleracea* could cause diarrhea to
274 the patient due to the ability to exacerbate the effect of acetylcholine, or constipation if given
275 at high doses.
276 According to [30], coumarins, anthraquinones and alkaloids are believed to have purgative
277 properties . However, phytochemical analysis revealed the presence of coumarins and
278 phenolic compounds in aqueous and hydroethanolic extracts from *N. oleracea*. The
279 presence of these compounds could justify the effect of *N. oleracea* extracts on
280 gastrointestinal transit.

281

282 **5. CONCLUSION**

283 This study allowed us to identify the different chemical groups present in aqueous and
284 hydro-ethanolic decoctions from *N. oleracea* leaves, to know the oral LD₅₀ of crude extracts
285 and the alkaloids fractions and to evaluate the interaction of these extracts on the smooth
286 muscle motricity. The phytochemical study revealed the presence of various chemical
287 compounds such as steroids, triterpenes, anthocyanosides, coumarins, tannins, saponins,
288 flavonids, etc. The acute oral toxicity study showed that this plant is weakly toxic by oral
289 route. The evaluation of the effect of the smooth muscle motricity showed that aqueous and
290 hydro-ethanolic extracts from *N. oleracea* stimulate basic bowel contractions at low dose but
291 induce inhibition of these contractions at high dose. In view of these results, we can say that
292 the many forms of use of this plant in traditional medicine can be justified by its richness in
293 secondary metabolites and its low toxicity.

294

295

296

297 **CONSENT**

298 Not applicable.

299

300 **ETHICAL APPROVAL**

301 The experimental protocol was carried out in accordance with international standard
302 protocols [Guidelines set by the European Union on the protection of animals (CEC Council
303 86/609)] and adopted by IRSS, Burkina Faso. These different experiments were carried out
304 on the mice and did not concern in any case the human subject. These protocols are ethical
305 to experiment on laboratory animals.

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

REFERENCES

1. Tabuti JRS, Lye KA, Dhillion SS. Traditional herbal drugs of Bulamogi, Uganda: Plants, use and administration. *J Ethnopharmacol.* 2003;88:19–44.
2. OMS B régional de L. Traditional medicine in Cambodia part one. 2011.
3. Zerbo P, Millogo-Rasolodimby J, Nacoulma-Ouedraogo OG, Van Damme P. Plantes médicinales et pratiques médicales au Burkina Faso : cas des Sanan. *Bois Forêts des Trop.* 2011;65:41–53.
4. Rohini N, Shanmugasundaram T, Pandiarana N. Review on Underutilized Vegetables for Human Health. 2017.
5. Bhoomannavar VS, Patil VP, Hugar S, Nanjappaiah HM, Kalyane N. Anti-ulcer activity of *Neptunia oleracea* Lour. *Pharmacologyonline.* 2011;3 January 2011:1015–20.
6. Lee SY, Mediani A, Ismail IS, Maulidiani, Abas F. Antioxidants and α -glucosidase inhibitors from *Neptunia oleracea* fractions using ¹H NMR-based metabolomics approach and UHPLC-MS/MS analysis 03 Chemical Sciences 0301 Analytical Chemistry. *BMC Complement Altern Med.* 2019;19:1–15.
7. Bhoomannavar VS, Shivakumar SI, Hallikeri CS, Hatapakki BC. Hepatoprotective activity of leaves of *Neptunia oleracea* Lour in carbon tetrachloride induced rats. *Res J Pharm Biol Chem Sci.* 2011;2:309–14.
8. Nakamura Y, Murakami A, Koshimizu K, Ohigashi H. Identification of Pheophorbide a and Its Related Compounds as Possible Anti-tumor Promoters in the Leaves of *Neptunia oleracea*. *Biosci Biotechnol Biochem.* 1996;60:1028–30.
9. Døssing M, Sonne J. Drug-Induced Hepatic Disorders: Incidence, Management and Avoidance. *Drug Saf.* 1993;9:441–9.
10. Thompson M, Jaiswal Y, Wang I, Williams L. Hepatotoxicity: Treatment, causes and applications of medicinal plants as therapeutic agents. *J Phytopharm.* 2017;6:186–93.
11. Yassir B et al. No Title. 2012.
12. Subha¹ D, Geetha N. Evaluation of acute toxicity of the methanolic extract of *Tanacetum parthenium* L. in albino wistar rats. *J Sci Innov Res.* 2017;6:113–5. www.jsirjournal.com.
13. MBODJ N. A. (2003). Etude de l'activité antidiabétique des extraits acétoniques, méthanoliques et hexaniques de *Vernonia colorata* (Wild / Drake) chez des rats wistar. Thèse de pharmacie Université Cheikh Anta Diop de Dakar; 2003. http://indexmedicus.afro.who.int/iah/fulltext/mbodj_ndeawa.pdf. Accessed 10 Aug 2019.
14. Ciulei. Practical Manuals on the Industrial Utilization of Medicinal and Aromatic Plants. Methodology for Analysis of Vegetable Drugs. 1st Edn. Bucarest; 1982.
15. OECD. OECD/OCDE 423 OECD GUIDELINE FOR TESTING OF CHEMICALS Acute Oral Toxicity-Acute Toxic Class Method. 2001. https://ntp.niehs.nih.gov/iccvm/suppdocs/feddocus/oecd/oecd_gl423.pdf. Accessed 10 Aug 2019.
16. Archange M, Tagne F, Kamgang R, Noubissi PA, Oyono J-LE. Activity of *Oxalis barleri* aqueous extract on rat secretory diarrhea and intestine transit. *J Appl Pharm Sci.* 2015;5:58–062. doi:10.7324/JAPS.2015.50111.
17. Schäfer H, Wink M. Medicinally important secondary metabolites in recombinant microorganisms or plants: Progress in alkaloid biosynthesis. *Biotechnol J.* 2009;4:1684–703.
18. Imane Z, Jihane I, Amal A, Souad S, Yassir B. Evaluation of the therapeutic and toxicological knowledge of herbalists on the most notified plants in the poison control and pharmacovigilance center of Morocco. *J Pharmacogn Phyther.* 2018;10:126–32.
19. Mole S, Butler LG, Iason G. Defense against dietary tannin in herbivores: A survey for proline rich salivary proteins in mammals. *Biochem Syst Ecol.* 1990;18:287–93. doi:10.1016/0305-1978(90)90073-O.
20. Nafuka SN, Mumbengegwi DR. Phytochemical Analysis and In Vitro Anti-plasmodial Activity of Selected Ethnomedicinal Plants Used to Treat Malaria Associated Symptoms in

- 359 Northern Namibia. 2013.
- 360 21. Soulama S, Sanon H, Meda R, Boussim J. Teneurs en tanins de 15 ligneux fourragers
361 du Burkina Faso. *Afrique Sci Rev Int des Sci Technol.* 2014;10:180–90.
362 <https://www.ajol.info/index.php/afsci/article/view/118347>.
- 363 22. World Health Organization. WHO human health risk assessment toolkit: chemical
364 hazards. World Health Organization; 2010.
- 365 23. United Nations. GLOBALLY HARMONIZED SYSTEM OF CLASSIFICATION AND
366 LABELLING OF CHEMICALS (GHS). ST/SG/AC.1. 2017.
367 https://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs_rev07/English/ST_SG_AC_10_30_Rev7e.pdf.
- 368
- 369 24. Roberts RR, Murphy JF, Young HM, Bornstein JC. Development of colonic motility in the
370 neonatal mouse-studies using spatiotemporal maps. *Am J Physiol - Gastrointest Liver*
371 *Physiol.* 2007;292:5–7.
- 372 25. Briet J, Javelot H, Vaillau JL. Échelle D'Imprégnation Anticholinergique : Mise Au Point
373 D'Une Nouvelle Échelle Incluant Les Molécules Françaises, Et Application En Psychiatrie.
374 *Eur Psychiatry.* 2015;30:S154–5.
- 375 26. Zimmerman TW, Dobbins JW, Binder HJ. Mechanism of cholinergic regulation of
376 electrolyte transport in rat colon in vitro. *Am J Physiol - Gastrointest Liver Physiol.* 1982;5.
- 377 27. Furness JB. The enteric nervous system and neurogastroenterology. *Nat Rev*
378 *Gastroenterol Hepatol.* 2012;9:286–94.
- 379 28. Holzer P. Opioid receptors in the gastrointestinal tract. *Regulatory Peptides.*
380 2009;155:11–7.
- 381 29. Wilcock SCA, Twycross R, Regnard C, Twycross R, Mihalyo M. *Therapeutic Reviews.*
382 2011;42:319–23.
- 383 30. Mamyrbekova-bekro JA, Boua BB, Bekro Y. Screening phytochimique bio guidé et
384 évaluation in vitro des propriétés purgatives de *Anchomanes difformis* (Blume) Engl ., une
385 plante utilisée en Côte d ' Ivoire dans le traitement folklorique de la constipation. 2013;:20–6.
386